{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:22Z","timestamp":1790351422432,"version":"4.1.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tyrosine-kinase inhibitors (TKIs) have reshaped chronic myeloid leukemia (CML) outcomes, but real-world data from Eastern Europe remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 201 adult patients with CML managed at the Cluj-Napoca Department of Haematology (January 2001\u2013December 2024). A semi-automated pipeline utilizing a Large Language Model was developed to extract structured data from unstructured medical discharge report text, with all patient identifiers removed to ensure anonymity. We captured demographics, disease phase, line-specific TKI use, adverse events (AEs), treatment-free remission (TFR) eligibility, TFR attempts, continuation, laboratory data and discontinuation. Machine learning models were trained to predict TFR potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients &amp;lt;60\u00a0years old, 101\/201 (50.2%), and \u226560 years old, 100\/201 (49.8%) were nearly equal in number. 53.7% were male. At diagnosis, 94.5% were in chronic phase. First-line treatment comprised imatinib in 108\/201 (53.7%), dasatinib in 56\/201 (27.9%), and nilotinib in 37\/201 (18.4%). Second-line therapy (\n                      <jats:italic>n<\/jats:italic>\n                      = 64) was dominated by dasatinib (64.1%) and nilotinib (28.1%). Third- and later-line regimens increasingly incorporated bosutinib, ponatinib, and asciminib. Fourteen patients (7.0%) achieved sustained treatment-free remission (TFR). Among these, 3 had received imatinib, 3 dasatinib, and 8 nilotinib. An additional 31 patients (15.4%) were TFR-eligible but still on therapy\u201416 of them after imatinib, 9 after dasatinib and 6 after nilotinib. Imatinib achieved MR4+ in 29% of exposures and nilotinib in 43.3% of third-line uses, underscoring its role as the cohort\u2019s most effective TFR-enabler. Predictive modelling for TFR potential using a Random Forest classifier achieved high accuracy (85.4%), with top predictors being whether a patient had ever achieved a deep molecular response (achieved_mr4_ever) and the best response after the first year (best_response_after_year1), highlighting the importance of both depth and timing of molecular remission. Adverse events led to discontinuation in 17\/105 imatinib (16.1%), 23\/105 dasatinib (21.9%), 9\/68 nilotinib (13.2%), 6\/13 bosutinib (46.2%), 4\/11 ponatinib (36.4%), and 2\/11 asciminib (18.2%) exposures. The most common imatinib discontinuation cause was loss of therapeutic response (34\/105; 32.4%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this Romanian center, imatinib was the predominant front-line TKI, reflecting both its earlier availability as the sole treatment option and the durable responses achieved by many long-term patients, but second-generation agents are increasingly used in over 40% of first-line starts. TFR uptake is limited despite a sizeable eligible population. Machine learning models demonstrate that both the depth and kinetics of molecular response are critical for predicting TFR potential. Prospective optimization of molecular monitoring and discontinuation protocols may broaden TFR success.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1673056","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:57:04Z","timestamp":1762426624000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR"],"prefix":"10.3389","volume":"16","author":[{"given":"Mihnea Lucian","family":"Micu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simion Florin","family":"Cira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Bojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrada","family":"Parvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Torok-Vistai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Vasilache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Urian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bancos","family":"Anamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Ioana","family":"Jimbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Elena","family":"Santa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lighezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Bogdan","family":"Tigu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Ivancuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Trifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Cristina","family":"Selicean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rus","family":"Ioana Codru\u021ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","article-title":"Risk factors for chronic myeloid leukemia","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.3390\/jcm13092567","article-title":"Treatment-free remission in chronic myeloid leukemia","volume":"13","author":"Bourne","year":"2024","journal-title":"J. Clin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/17474086.2024.2440776","article-title":"Understanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)","volume":"18","author":"Lagan\u00e0","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s41416-023-02387-8","article-title":"Radiation exposure and leukaemia risk among cohorts of persons exposed to low and moderate doses of external ionising radiation in childhood","volume":"129","author":"Little","year":"2023","journal-title":"Br. J. Cancer"},{"key":"B9","article-title":"Cancer stat facts: leukemia\u2014chronic myeloid leukemia (CML)","year":"2025","journal-title":"SEER"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1002\/cncr.35038","article-title":"Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-the surveillance, epidemiology, and end results database, 2000-2019","volume":"129","author":"Sasaki","year":"2023","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Shah","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B13","volume-title":"FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2284038","DOI":"10.1080\/16078454.2023.2284038","article-title":"A review on characterization of BCR - ABL transcript variants for molecular monitoring of chronic myeloid leukemia phenotypes","volume":"28","author":"Zenebe","year":"2023","journal-title":"Hematology."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1673056\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:57:06Z","timestamp":1762426626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1673056\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":14,"alternative-id":["10.3389\/fphar.2025.1673056"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1673056","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1673056"}}